Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 29 | 2025 | 383 | 5.130 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 11 | 2024 | 42 | 1.770 |
Why?
|
| Immunosuppressive Agents | 17 | 2025 | 672 | 1.070 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2021 | 18 | 0.700 |
Why?
|
| Meningoencephalitis | 1 | 2021 | 22 | 0.700 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 20 | 0.700 |
Why?
|
| JC Virus | 1 | 2021 | 28 | 0.690 |
Why?
|
| Cross Infection | 1 | 2024 | 342 | 0.680 |
Why?
|
| Fingolimod Hydrochloride | 5 | 2024 | 35 | 0.660 |
Why?
|
| Interferon-beta | 6 | 2011 | 54 | 0.640 |
Why?
|
| Recurrence | 7 | 2025 | 1469 | 0.620 |
Why?
|
| Glioblastoma | 1 | 2021 | 363 | 0.520 |
Why?
|
| Ganglioglioma | 1 | 2016 | 20 | 0.500 |
Why?
|
| Dimethyl Fumarate | 4 | 2024 | 10 | 0.490 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2025 | 35 | 0.440 |
Why?
|
| Glatiramer Acetate | 5 | 2025 | 15 | 0.370 |
Why?
|
| Brain Diseases | 2 | 2019 | 305 | 0.360 |
Why?
|
| Osteopontin | 1 | 2010 | 52 | 0.330 |
Why?
|
| Young Adult | 11 | 2025 | 9958 | 0.320 |
Why?
|
| Interleukin-17 | 1 | 2010 | 129 | 0.320 |
Why?
|
| Adult | 28 | 2025 | 31575 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2021 | 1200 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2021 | 3831 | 0.300 |
Why?
|
| Injections, Epidural | 1 | 2008 | 5 | 0.300 |
Why?
|
| Pneumocephalus | 1 | 2008 | 4 | 0.300 |
Why?
|
| Lateral Ventricles | 1 | 2008 | 16 | 0.300 |
Why?
|
| Dura Mater | 1 | 2008 | 25 | 0.290 |
Why?
|
| Sarcoidosis | 1 | 2008 | 57 | 0.280 |
Why?
|
| Headache | 1 | 2008 | 110 | 0.280 |
Why?
|
| Immunologic Factors | 5 | 2024 | 183 | 0.280 |
Why?
|
| Middle Aged | 21 | 2025 | 28998 | 0.270 |
Why?
|
| Crotonates | 2 | 2024 | 6 | 0.270 |
Why?
|
| Humans | 45 | 2025 | 132089 | 0.270 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1378 | 0.250 |
Why?
|
| Adolescent | 15 | 2025 | 20560 | 0.220 |
Why?
|
| Female | 28 | 2025 | 70695 | 0.220 |
Why?
|
| Toluidines | 1 | 2024 | 4 | 0.220 |
Why?
|
| Hydroxybutyrates | 1 | 2024 | 30 | 0.220 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 121 | 0.210 |
Why?
|
| Male | 25 | 2025 | 64967 | 0.210 |
Why?
|
| Nitriles | 1 | 2024 | 154 | 0.200 |
Why?
|
| Intracranial Hypertension | 1 | 2025 | 133 | 0.200 |
Why?
|
| Brain | 6 | 2021 | 3176 | 0.190 |
Why?
|
| Immunotherapy | 2 | 2024 | 745 | 0.190 |
Why?
|
| Cost of Illness | 2 | 2020 | 285 | 0.190 |
Why?
|
| Methotrexate | 3 | 2009 | 350 | 0.180 |
Why?
|
| Retrospective Studies | 13 | 2025 | 17416 | 0.180 |
Why?
|
| Urinary Retention | 1 | 2021 | 19 | 0.180 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 17 | 0.180 |
Why?
|
| Herpes Simplex | 1 | 2022 | 56 | 0.180 |
Why?
|
| Alemtuzumab | 2 | 2020 | 88 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 3 | 2009 | 391 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2024 | 414 | 0.170 |
Why?
|
| Health Expenditures | 2 | 2020 | 133 | 0.160 |
Why?
|
| Methylprednisolone | 3 | 2009 | 98 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2020 | 54 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 7104 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 125 | 0.150 |
Why?
|
| Autoantibodies | 3 | 2025 | 456 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 576 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 635 | 0.130 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 105 | 0.120 |
Why?
|
| Aged | 7 | 2025 | 21438 | 0.120 |
Why?
|
| Spinal Cord | 4 | 2021 | 267 | 0.120 |
Why?
|
| Dendritic Cells | 2 | 2011 | 448 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2021 | 13034 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 1028 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1500 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2025 | 14749 | 0.090 |
Why?
|
| Quality of Life | 1 | 2022 | 2161 | 0.090 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2011 | 2 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2011 | 677 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2009 | 305 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2016 | 908 | 0.090 |
Why?
|
| Lymphocyte Activation | 2 | 2011 | 679 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8549 | 0.090 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 54 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2024 | 698 | 0.080 |
Why?
|
| Child | 4 | 2025 | 25786 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1131 | 0.080 |
Why?
|
| United States | 5 | 2025 | 11667 | 0.080 |
Why?
|
| Infant | 2 | 2024 | 13061 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 228 | 0.080 |
Why?
|
| Linear Models | 2 | 2022 | 713 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 876 | 0.070 |
Why?
|
| Bupivacaine | 1 | 2008 | 28 | 0.070 |
Why?
|
| Atrophy | 3 | 2021 | 252 | 0.070 |
Why?
|
| Low Back Pain | 1 | 2008 | 40 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5416 | 0.070 |
Why?
|
| Transplantation, Autologous | 3 | 2017 | 286 | 0.070 |
Why?
|
| Neuromyelitis Optica | 1 | 2008 | 33 | 0.070 |
Why?
|
| Prednisone | 1 | 2008 | 253 | 0.070 |
Why?
|
| Biopsy | 2 | 2008 | 1284 | 0.070 |
Why?
|
| Steroids | 1 | 2008 | 173 | 0.070 |
Why?
|
| Antibodies, Neoplasm | 1 | 2007 | 59 | 0.070 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 21 | 0.070 |
Why?
|
| Roseolovirus Infections | 1 | 2007 | 30 | 0.070 |
Why?
|
| Interferon beta-1a | 4 | 2009 | 20 | 0.060 |
Why?
|
| Meningioma | 1 | 2008 | 134 | 0.060 |
Why?
|
| Herpesvirus 6, Human | 1 | 2007 | 55 | 0.060 |
Why?
|
| Disability Evaluation | 3 | 2017 | 198 | 0.060 |
Why?
|
| Logistic Models | 2 | 2022 | 1839 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 212 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 1160 | 0.060 |
Why?
|
| Drugs, Investigational | 1 | 2005 | 24 | 0.060 |
Why?
|
| Financing, Personal | 1 | 2004 | 16 | 0.060 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2004 | 21 | 0.060 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2024 | 7 | 0.050 |
Why?
|
| Optic Neuritis | 1 | 2025 | 34 | 0.050 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 15 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 67 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2005 | 172 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 959 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 106 | 0.050 |
Why?
|
| Epitopes | 1 | 2005 | 436 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 233 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1952 | 0.050 |
Why?
|
| Peptides | 2 | 2004 | 846 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2004 | 617 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 342 | 0.050 |
Why?
|
| Interferon Type I | 1 | 2002 | 114 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2004 | 249 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 8 | 0.050 |
Why?
|
| Medicare | 1 | 2025 | 448 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 5168 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3766 | 0.040 |
Why?
|
| Injections | 1 | 2021 | 152 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1355 | 0.040 |
Why?
|
| Constipation | 1 | 2021 | 128 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2169 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 61 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 1163 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2023 | 329 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 428 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 78 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2019 | 99 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 84 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 294 | 0.040 |
Why?
|
| Lactation | 1 | 2020 | 198 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 2658 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 154 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1254 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2004 | 1743 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 230 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2011 | 3037 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1882 | 0.030 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 232 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3739 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 1179 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 553 | 0.030 |
Why?
|
| Patient Selection | 2 | 2009 | 737 | 0.030 |
Why?
|
| Disease Progression | 2 | 2015 | 2225 | 0.030 |
Why?
|
| Risk Factors | 2 | 2024 | 10946 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 768 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 800 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1722 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 4003 | 0.020 |
Why?
|
| Clonal Anergy | 1 | 2011 | 5 | 0.020 |
Why?
|
| Natalizumab | 1 | 2011 | 3 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2011 | 64 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2004 | 664 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1900 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1284 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1294 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2008 | 20 | 0.020 |
Why?
|
| Autopsy | 1 | 2007 | 114 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 22 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7555 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 366 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2008 | 386 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2007 | 487 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 806 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 304 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 652 | 0.010 |
Why?
|
| Chad | 1 | 2004 | 1 | 0.010 |
Why?
|
| Axons | 1 | 2007 | 390 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 135 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 33 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 52 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 119 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 100 | 0.010 |
Why?
|
| Income | 1 | 2004 | 139 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 295 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 343 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3861 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1548 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2140 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 354 | 0.010 |
Why?
|
| Data Collection | 1 | 2004 | 391 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 187 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 743 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 4754 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 534 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 1044 | 0.010 |
Why?
|
| Poverty | 1 | 2004 | 446 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 348 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 1347 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 493 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1960 | 0.010 |
Why?
|
| Cytokines | 1 | 2002 | 1359 | 0.010 |
Why?
|
| Animals | 2 | 2011 | 34798 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 18466 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6448 | 0.010 |
Why?
|